Organ preservation and transport company Paragonix Technologies has agreed to be acquired through a $477 million deal offered by Getinge—which expects the international transplant market to continue ...

In its second acquisition of 2023—and its largest in several years—Swedish devicemaker Getinge has set its sights on High Purity New England, which churns out a range of products used throughout the ...

Q3 adj. EBITA and sales miss analysts' forecasts Orders keep growing organically at 7.4% Deliveries restarted after temporary disruptions in Q3, CEO says Shares fall 6.9% by midday local time Oct 18 ...

Price hikes and cost saving measures aid Getinge's earnings growth Absorbs chunk of near-term tariff costs before pricing measures fully bite US probe into medtech imports doesn't affect Getinge, CEO ...

Getinge’s decision to leave the surgical perfusion market will benefit LivaNova, an already dominant player in the sector ...

GOTHENBURG, Sweden, March 27, 2025 /PRNewswire/ -- Today, Getinge publishes its Annual Report, including Sustainability Report, for 2024. The report summarizes a year characterized by strong growth, ...

Getinge has today completed the previously announced acquisition of 100% of the shares of Paragonix Technologies, Inc. The total market for transplants has been growing rapidly in recent years and is ...

Organic Net Sales Growth: 9.5% increase. Order Intake Growth: 4.7% increase organically. Adjusted Gross Profit: SEK4.51 million. Adjusted EBITDA: SEK179 million, margin improved to 13.1%. Tariff Costs ...

Getinge AB is a Swedish healthcare medical tech company with a $5 billion market cap and leading positions in multiple niches within its target markets. The company has faced headwinds in recent years ...

Getinge has faced ongoing operational issues and regulatory challenges, but recent investments in quality control may signal an improvement. Market sentiment remains negative due to historical biases, ...